StreetAlpha.app
Home › Stocks › BLLN

BillionToOne, Inc. (BLLN)

Healthcare
$97.50
▲ +1.24%
LAST CLOSE · NOV 17

BillionToOne sells genetic blood tests for prenatal screening and cancer care to doctors and clinics. It last closed at $97.50 on Nov 17, up 1.24% on the day. BLLN last reported earnings on Tue, Oct 6, 2026. The average 12-month price target from 4 analysts is $128.25 (+31.5% from the last close), with a high of $135.00 and a low of $120.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in BLLN, 100% of them bullish and 0% bearish.

AI Auto Pilots
Is BLLN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$436.9M
+71.9% vs a year ago
Net income
$49.4M
11.3% margin
EPS (diluted)
$0.92
Free cash flow
$33.9M
7.8% margin
Balance sheet
Cash & equivalents
$561.5M
At Sep 30
Debt
$89.0M
At Sep 30
Shareholder equity
$566.5M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $71.7M$71.7MFY2023FY2024: $152.6M$152.6MFY2024FY2025: $305.1M$305.1MFY2025

From BLLN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Last report
Oct 6
2026 · Time not announced
Reported EPS
$0.15
vs $0.15 est. · inline
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on BLLN in the past 90 days
Average 12-month target
$128.25
▲ 31.5% upside

Based on 4 analysts who set a price target on BLLN in the past 90 days. The average target is $128.25, with a high of $135.00 and a low of $120.00, compared with the last close of $97.50.

Low $120.00Avg $128.25High $135.00
Blue marker: last close $97.50
Highest target$135.00
Average target$128.25
Lowest target$120.00
Latest rating changes
Piper SandlerMaintained
Nov 10Buy$130
JP MorganTarget raised
Nov 5Buy$130 → $135
GuggenheimTarget raised
Oct 1Buy$125 → $128
Canaccord GenuityInitiated
Sep 2Buy$120
JP MorganMaintained
Aug 6Buy$130
DateFirmActionRatingPrice target
Nov 10Piper SandlerMaintainedBuy$130
Nov 5JP MorganTarget raisedBuy$130 → $135
Oct 1GuggenheimTarget raisedBuy$125 → $128
Sep 2Canaccord GenuityInitiatedBuy$120
Aug 6JP MorganMaintainedBuy$130
Loading…

Technical Analysis

BLLN · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, nearing oversold

The stock is 12% below its 20 day and 10% below its 50 day average. It is sitting right on its 200 day average, a level many traders watch. Momentum is weak (RSI 36), near oversold. The nearest support is the Pivot at $97.20, and the nearest resistance the 200 day average at $97.79.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 6.8%/day
Key levels
$150.4452 week high+54.3%
$110.14100 day average+13.0%
$109.6920 day average+12.5%
$106.9050 day average+9.6%
$100.30Pivot R1+2.9%
$100.00Swing high (May 29)+2.6%
$97.79200 day average+0.3%
$97.50Last close
$97.20Pivot−0.3%
$95.23Swing low (Sep 11)−2.3%
$94.41Pivot S1−3.2%
$61.9652 week low−36.5%
Indicators
RSI (14)36.46Weak, oversold below 30Neutral
MACD-0.77Below its signal lineBearish
Stochastic15.5Near the bottom of its rangeOversold
ADX (14)17.0No clear trend
Williams %R-85.8Oversold below −80, overbought above −20Oversold
CCI (20)-213.8Oversold below −100, overbought above 100Oversold
Rate of change−11.7%Change over 10 sessionsBearish
ATR (14)$6.65Typical daily range, 6.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BLLN

What happened before

See how BLLN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Sep 24 – Sep 24
Loading…

See today’s whale options flow across the market →

BLLN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲117 buying vs 69 selling
  • ▲Shares held by funds +21.1%
  • ▲Funds holding +16
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding172156+10.3%
In funds' top 1047−42.9%
Held by funds–––
New / increased48 / 6977 / 49−7.1%
Reduced / sold out37 / 3213 / 11+187.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BLLN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BLLN is in one of them and how their past BLLN trades turned out.

BLLN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BLLN in an article yet. Here's the latest on the wider market.

About BillionToOne

BillionToOne is a molecular diagnostics company based in Menlo Park, California. It offers genetic tests that analyze cell free DNA from a blood sample, using a sequencing method that counts individual DNA molecules. Its prenatal test, UNITY, assesses fetal genetic risk from a single maternal blood draw. Its Northstar tests are cancer tests used by oncology providers to help select treatments and track how patients respond to therapy.

Headquarters
Menlo Park, CA